Medical Condition News

RSS

RCT licensee Dyax receives approval from the FDA for KALBITOR

RCT licensee Dyax Corp. has received approval from the U.S. Food and Drug Administration for KALBITOR® (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.

7 Dec 2009

Two Brown University faculty members receive federal funding for new neuroscience research projects

Two Brown University faculty members have received federal funding for innovative new neuroscience research projects focusing on brain development in infants and bipolar disorder in children.

7 Dec 2009

Cysteine-rich whey protein supplement may maintain or increase weight in advanced NSCLC patients

Immunotec Inc. announced today the enrollment of the first patient in the US Cancer trial of IMN 1207 being run at Beaumont Hospital's Community Clinical Oncology Program (CCOP) in Royal Oak, Michigan. The goal of the study is to determine the effect of IMN 1207, a cysteine-rich whey protein supplement, in preventing additional weight loss in patients with stage IV (advanced) non-small cell lung cancer.

7 Dec 2009

New data from Allos Therapeutics' FOLOTYN trial for PTCL

Allos Therapeutics, Inc. today reported a new analysis of data from the Company’s pivotal PROPEL trial of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated.

7 Dec 2009

Study data of Perifosine + Bortezomib combination in multiple myeloma patients presented

Æterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its partner Keryx Biopharmaceuticals Inc. reported updated efficacy and safety data as well as new survival data on the clinical activity of perifosine (KRX-0401) in combination with bortezomib (Velcade(R)) (+/- dexamethasone) in patients with relapsed/refractory multiple myeloma.

7 Dec 2009

$225,000 funding for promising epilepsy research

The Epilepsy Research Foundation (ERF), a unique joint venture of non-profit epilepsy organizations, and the Milken Family Foundation, a private philanthropic foundation, today announced two new grants recognizing promising epilepsy research in clinical development, totaling $225,000 in funding. The grant awards were announced by the Epilepsy Therapy Project and the Epilepsy Foundation, as well as the Milken Family Foundation, during the 7th Judith Hoyer Lecture in Epilepsy at the annual meeting of the American Epilepsy Society in Boston, MA.

7 Dec 2009

Incyte's INCB18424 provides previously unachievable clinical benefits in myelofibrosis patients

Incyte Corporation announced this morning that INCB18424 (also referred to as INCB018424), its selective, orally available janus kinase (JAK) inhibitor, will be the subject of three oral presentations at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans.

7 Dec 2009

Interim data from Celator Pharmaceuticals' CPX-351 trial presented at the ASH meeting

Celator Pharmaceuticals today announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML) were presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana (ASH Abstract # 1033).

7 Dec 2009

Synta Pharmaceuticals announces study results of elesclomol

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced the results of a study evaluating the activity of elesclomol against acute myeloid leukemia (AML) cell lines and primary leukemic blast cells from AML patients, presented at the Annual Meeting of the American Society of Hematology (ASH) in New Orleans.

7 Dec 2009

FDA provides a Complete Response Letter for Somaxon Pharmaceuticals' Silenor NDA

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that the company has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.

7 Dec 2009

Æterna Zentaris reports Phase 3 results of its cetrorelix pamoate Z-036 trial for BPH

Æterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia (BPH), with cetrorelix pamoate.

7 Dec 2009

Encouraging data from Seattle Genetics' phase I trial of brentuximab vedotin

Seattle Genetics, Inc. today reported data from a phase I weekly-dosing clinical trial of brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC), including multiple complete and partial remissions in patients with relapsed or refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma (ALCL).

7 Dec 2009

Micromet to present new data from its blinatumomab Phase 1 trial at the ASH meeting

Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the publication of a poster with new data from its ongoing phase 1 clinical trial of its product candidate blinatumomab in patients with non-Hodgkin's lymphoma (NHL) at the 51ST Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana.

7 Dec 2009

Atrium Medical commences enrollment in its INFUSE AMI trial

Atrium Medical Corporation announced that the 1st patient was enrolled in the INFUSE AMI trial. INFUSE AMI is a multi-center, multi-national, prospective, randomized, single blind trial examining how patients with heart attacks are treated. The study's aim is to help determine the best way to treat patients with an acute anterior wall myocardial infarction (acute MI) with ST segment elevation, commonly referred to as STEMIs.

7 Dec 2009

UCB presents data on Vimpat AED at AES meeting

UCB today announced new findings on its antiepileptic drug (AED) Vimpat® that offer additional clinical evidence supporting the use of this AED as adjunctive therapy in adult patients with partial-onset seizures. Results of presented research demonstrate sustained efficacy in adult patients taking Vimpat® for up to three years, and a consistent long-term tolerability profile.

7 Dec 2009

New study reveals RNA may play a critical role in cancer treatment

Researchers from Yale University and Mirna Therapeutics, Inc., reversed the growth of lung tumors in mice using a naturally occurring tumor suppressor microRNA. The study reveals that a tiny bit of RNA may one day play a big role in cancer treatment, and provides hope for future patients battling one of the most prevalent and difficult to treat cancers.

7 Dec 2009

Discovery presents a vital step towards efficient treatment of vascular injuries

Hyperglycemia starts a complex chain of events that damages blood vessels and cause cardiovascular disease. Scientists at Lund University Diabetes Centre (LUDC) have now been able to demonstrate why this happens, as well as how the destructive chain can be broken.

7 Dec 2009

Kidneys from donors with renal masses to address the current organ shortage

Surgeons who successfully performed kidney transplants after removing small cancerous and benign masses from the donated organs, have published their results in the December issue of the UK-based urology journal BJUI.

7 Dec 2009

Dabigatran etexilate prevents recurrent VTE with less bleeding than warfarin

Boehringer Ingelheim today announced very positive results from their landmark RE-COVER™ study – the most advanced trial programme assessing a novel oral anticoagulant in development for acute venous thromboemolism (VTE) treatment – presented at the American Society of Hematology Annual Meeting1 and published in the New England Journal of Medicine online.

7 Dec 2009

New oral drug is safe and effective to combat clotting disorder

A new study provides welcome news for patients with a common clotting disorder known as venous thromboembolism (VTE).

7 Dec 2009

Medical Condition News

RCT licensee Dyax receives approval from the FDA for KALBITOR

Two Brown University faculty members receive federal funding for new neuroscience research projects

Cysteine-rich whey protein supplement may maintain or increase weight in advanced NSCLC patients

New data from Allos Therapeutics' FOLOTYN trial for PTCL

Study data of Perifosine + Bortezomib combination in multiple myeloma patients presented

$225,000 funding for promising epilepsy research

Incyte's INCB18424 provides previously unachievable clinical benefits in myelofibrosis patients

Interim data from Celator Pharmaceuticals' CPX-351 trial presented at the ASH meeting

Synta Pharmaceuticals announces study results of elesclomol

FDA provides a Complete Response Letter for Somaxon Pharmaceuticals' Silenor NDA

Æterna Zentaris reports Phase 3 results of its cetrorelix pamoate Z-036 trial for BPH

Encouraging data from Seattle Genetics' phase I trial of brentuximab vedotin

Micromet to present new data from its blinatumomab Phase 1 trial at the ASH meeting

Atrium Medical commences enrollment in its INFUSE AMI trial

UCB presents data on Vimpat AED at AES meeting

New study reveals RNA may play a critical role in cancer treatment

Discovery presents a vital step towards efficient treatment of vascular injuries

Kidneys from donors with renal masses to address the current organ shortage

Dabigatran etexilate prevents recurrent VTE with less bleeding than warfarin

New oral drug is safe and effective to combat clotting disorder

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News